{"DataElement":{"publicId":"6788092","version":"1","preferredName":"Amyloid Fibril-Directed Therapy Administered Type","preferredDefinition":"A description of the amyloid fibril-directed therapy that was administered.","longName":"6788083v1.0:6788086v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6788083","version":"1","preferredName":"Amyloid Fibril-Directed Therapy Administered","preferredDefinition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance._The act of having given something (e.g., a medication or test).","longName":"6788081v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6788081","version":"1","preferredName":"Amyloid Fibril-Directed Therapy","preferredDefinition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","longName":"C161823","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloid Fibril-Directed Therapy","conceptCode":"C161823","definition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DAD7-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DAE5-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6788086","version":"1","preferredName":"Amyloid Fibril-Directed Therapy Type","preferredDefinition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance._Something distinguishable as an identifiable class based on common qualities.","longName":"6788086v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"EGCG / green tea","valueDescription":"Epigallocatechin Gallate And/Or Green Tea Amyloid Fibril-Directed Therapy","ValueMeaning":{"publicId":"6788094","version":"1","preferredName":"Epigallocatechin Gallate And/Or Green Tea Amyloid Fibril-Directed Therapy","longName":"6788094","preferredDefinition":"A phenolic antioxidant found in a number of plants such as green and black tea. It inhibits cellular oxidation and prevents free radical damage to cells. It is under study as a potential cancer chemopreventive agent. (NCI): Used to indicate that either or both of two items or options may be valid.: Tea derived from the dried leaves of the plant Camellia sinensis with potential antioxidant, chemopreventive, and lipid-lowering activities. Green tea contains polyphenols that are believed to be responsible for its chemopreventive effect. The polyphenol fraction contains mainly Epigallocatechin-3-gallate (EGCG) and other catechins, such as epicatechin (EC), gallocatechin gallate (GCG), epigallocatechin (EGC), and epicatechin gallate (ECG). Green tea polyphenols act as antioxidants and free radical scavengers and may affect enzymes involved in cellular replication and tumor angiogenesis by modulating angiogenic factors, such as vascular endothelial growth factor (VEGF).: Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epigallocatechin Gallate","conceptCode":"C1088","definition":"A phenolic antioxidant found in a number of plants such as green and black tea. It inhibits cellular oxidation and prevents free radical damage to cells. It is under study as a potential cancer chemopreventive agent. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Green Tea","conceptCode":"C67048","definition":"Tea derived from the dried leaves of the plant Camellia sinensis with potential antioxidant, chemopreventive, and lipid-lowering activities. Green tea contains polyphenols that are believed to be responsible for its chemopreventive effect. The polyphenol fraction contains mainly Epigallocatechin-3-gallate (EGCG) and other catechins, such as epicatechin (EC), gallocatechin gallate (GCG), epigallocatechin (EGC), and epicatechin gallate (ECG). Green tea polyphenols act as antioxidants and free radical scavengers and may affect enzymes involved in cellular replication and tumor angiogenesis by modulating angiogenic factors, such as vascular endothelial growth factor (VEGF).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Amyloid Fibril-Directed Therapy","conceptCode":"C161823","definition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC1A634-7AE3-5B69-E053-F662850A2D5C","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BC1A634-7AFC-5B69-E053-F662850A2D5C","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BC12CF5-DB25-78F7-E053-F662850AC8C1","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","deletedIndicator":"No"},{"value":"NEOD - 001","valueDescription":"Anti-amyloid Monoclonal Antibody NEOD001","ValueMeaning":{"publicId":"6788088","version":"1","preferredName":"Anti-amyloid Monoclonal Antibody NEOD001","longName":"6788088","preferredDefinition":"A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, anti-amyloid monoclonal antibody NEOD001 specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-amyloid Monoclonal Antibody NEOD001","conceptCode":"C106248","definition":"A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, anti-amyloid monoclonal antibody NEOD001 specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DB32-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BC12CF5-DB4B-78F7-E053-F662850AC8C1","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","deletedIndicator":"No"},{"value":"CAEL - 101","valueDescription":"Chimeric Fibril-reactive Monoclonal Antibody 111F4","ValueMeaning":{"publicId":"6788089","version":"1","preferredName":"Chimeric Fibril-reactive Monoclonal Antibody 111F4","longName":"6788089","preferredDefinition":"A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, chimeric fibril-reactive monoclonal antibody 111F4 targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anselamimab","conceptCode":"C117241","definition":"A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DB57-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BC12CF5-DB70-78F7-E053-F662850AC8C1","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","deletedIndicator":"No"},{"value":"Doxycycline","valueDescription":"Doxycycline","ValueMeaning":{"publicId":"3874894","version":"1","preferredName":"Doxycycline","longName":"3874894","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E595BB41-EE07-FBF1-E040-BB89AD435381","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BC12CF5-DBA3-78F7-E053-F662850AC8C1","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6788085","version":"1","preferredName":"Amyloid Fibril-Directed Therapy Type","preferredDefinition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.:Something distinguishable as an identifiable class based on common qualities.","longName":"C161823:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloid Fibril-Directed Therapy","conceptCode":"C161823","definition":"Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DAFE-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC12CF5-DB0F-78F7-E053-F662850AC8C1","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the amyloid fibril-d","type":"Preferred Question Text","description":"What was the amyloid fibril-directed therapy that was administered?","url":null,"context":"NHLBI"},{"name":"Specify amyloid fibril-directed therapies","type":"Alternate Question Text","description":"Specify amyloid fibril-directed therapies","url":null,"context":"NHLBI"},{"name":"Specify amyloid fibril-directed therapies","type":"Application Standard Question Text","description":"Specify amyloid fibril-directed therapies","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC18703-E726-7124-E053-F662850AC95F","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}